

# Beth M Piraino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/29269/publications.pdf>

Version: 2024-02-01

165  
papers

8,495  
citations

57758

44  
h-index

46799

89  
g-index

170  
all docs

170  
docs citations

170  
times ranked

4058  
citing authors

#	ARTICLE	IF	CITATIONS
1	Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. <i>Peritoneal Dialysis International</i> , 2010, 30, 393-423.	2.3	770
2	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. <i>Peritoneal Dialysis International</i> , 2016, 36, 481-508.	2.3	745
3	Peritoneal dialysis-related infections recommendations: 2005 update. <i>Peritoneal Dialysis International</i> , 2005, 25, 107-31.	2.3	304
4	ISPD Position Statement on Reducing the Risks of Peritoneal Dialysis-Related Infections. <i>Peritoneal Dialysis International</i> , 2011, 31, 614-630.	2.3	273
5	Randomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 539-545.	6.1	223
6	A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. <i>American Journal of Kidney Diseases</i> , 1996, 27, 695-700.	1.9	217
7	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. <i>Peritoneal Dialysis International</i> , 2022, 42, 110-153.	2.3	209
8	Charlson Comorbidity Index as a Predictor of Outcomes in Incident Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2001, 37, 337-342.	1.9	203
9	Reviews and Original Articles. <i>Peritoneal Dialysis International</i> , 1996, 16, 557-573.	2.3	192
10	Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. <i>General Hospital Psychiatry</i> , 2006, 28, 306-312.	2.4	180
11	A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1055-1065.	1.9	179
12	Sleep Apnea in Patients on Conventional Thrice-Weekly Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3503-3509.	6.1	156
13	The Influence of Peritoneal Catheter Exit-Site Infections on Peritonitis, Tunnel Infections, and Catheter Loss in Patients on Continuous Ambulatory Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1986, 8, 436-440.	1.9	126
14	Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>American Journal of Kidney Diseases</i> , 2020, 76, 42-53.	1.9	120
15	Comparison of Infectious Complications between Incident Hemodialysis and Peritoneal Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1226-1233.	4.5	113
16	A Five-Year Study of the Microbiologic Results of Exit Site Infections and Peritonitis in Continuous Ambulatory Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1987, 10, 281-286.	1.9	105
17	Peritonitis associated with exit site and tunnel infections. <i>American Journal of Kidney Diseases</i> , 1996, 28, 415-419.	1.9	103
18	Albumin at the start of peritoneal dialysis predicts the development of peritonitis. <i>American Journal of Kidney Diseases</i> , 2003, 41, 664-669.	1.9	88

#	ARTICLE	IF	CITATIONS
19	Randomized controlled trial of SPIRIT: An effective approach to preparing African-American dialysis patients and families for end of life. <i>Research in Nursing and Health</i> , 2009, 32, 260-273.	1.6	88
20	Large Body Mass Index does not Predict Short-Term Survival in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 191-196.	2.3	84
21	Prevalence and Correction of 25(OH) Vitamin D Deficiency in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2005, 25, 362-366.	2.3	84
22	Catheter Infections as a Factor in the Transfer of Continuous Ambulatory Peritoneal Dialysis Patients to Hemodialysis. <i>American Journal of Kidney Diseases</i> , 1989, 13, 365-369.	1.9	81
23	Infecting Organisms in Continuous Ambulatory Peritoneal Dialysis Patients on the Y-set. <i>American Journal of Kidney Diseases</i> , 1994, 23, 569-573.	1.9	81
24	Continuous Cycling Peritoneal Dialysis Is Associated With Lower Rates of Catheter Infections Than Continuous Ambulatory Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1990, 16, 133-136.	1.9	79
25	Pattern of noncompliance with dialysis exchanges in peritoneal dialysis patients. <i>American Journal of Kidney Diseases</i> , 2000, 35, 1104-1110.	1.9	79
26	Serum Electrolyte Patterns in End-Stage Renal Disease. <i>American Journal of Kidney Diseases</i> , 1986, 8, 98-104.	1.9	78
27	Hemoperitoneum Complicating Chronic Peritoneal Dialysis: Single-Center Experience and Literature Review. <i>American Journal of Kidney Diseases</i> , 1992, 19, 252-256.	1.9	77
28	Hospitalization in peritoneal dialysis patients. <i>American Journal of Kidney Diseases</i> , 1999, 33, 927-933.	1.9	76
29	Subjective and Objective Sleep Quality in Patients on Conventional Thrice-Weekly Hemodialysis: Comparison With Matched Controls From the Sleep Heart Health Study. <i>American Journal of Kidney Diseases</i> , 2008, 52, 305-313.	1.9	76
30	Staphylococcus Aureus Prophylaxis and Trends in Gram-Negative Infections in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 456-459.	2.3	74
31	Polymicrobial Peritonitis in Patients on Continuous Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1992, 19, 162-166.	1.9	72
32	Systematic Barriers to the Effective Delivery of Home Dialysis in the United States: A Report From the Public Policy/Advocacy Committee of the North American Chapter of the International Society for Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 2011, 58, 879-885.	1.9	68
33	Effects of an intervention to improve communication about end-of-life care among African Americans with chronic kidney disease. <i>Applied Nursing Research</i> , 2010, 23, 65-72.	2.2	67
34	Analysis of continuous ambulatory peritoneal dialysis-related pseudomonas aeruginosa infections. <i>American Journal of Medicine</i> , 1987, 83, 829-832.	1.5	66
35	PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Quality of Life and Psychological Issues in Peritoneal Dialysis Patients. <i>Seminars in Dialysis</i> , 2008, 18, 119-123.	1.3	64
36	The Effect of Depressive Symptoms on Survival in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2004, 24, 256-263.	2.3	57

#	ARTICLE	IF	CITATIONS
37	Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2118-2126.	0.7	56
38	The Effect of Body Weight on CAPD Related Infections and Catheter Loss. <i>Peritoneal Dialysis International</i> , 1991, 11, 64-68.	2.3	55
39	Comparison of the Charlson Comorbidity Index and the Davies Score as a Predictor of Outcomes in PD Patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 568-573.	2.3	55
40	A Review of Staphylococcus S aureus Exit-Site and Tunnel Infections in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 1990, 16, 89-95.	1.9	52
41	Staphylococcus Aureus Infections in Dialysis Patients: Focus on Prevention. <i>ASAIO Journal</i> , 2000, 46, S13-S17.	1.6	49
42	Bleeding Complications Associated with Peritoneal Dialysis Catheter Insertion. <i>Peritoneal Dialysis International</i> , 2004, 24, 478-480.	2.3	42
43	Design, feasibility, and acceptability of an intervention using personal digital assistant-based self-monitoring in managing type 2 diabetes. <i>Contemporary Clinical Trials</i> , 2008, 29, 396-409.	1.8	42
44	Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2005, 25, 362-6.	2.3	42
45	No Difference in Average Interdialytic Weight Gain Observed in a Randomized Trial With a Technology-Supported Behavioral Intervention to Reduce Dietary Sodium Intake in Adults Undergoing Maintenance Hemodialysis in the United States: Primary Outcomes of the BalanceWise Study. , 2016, 26, 149-158.		38
46	Peritoneal Eosinophils during Intermittent Peritoneal Dialysis. <i>American Journal of Nephrology</i> , 1984, 4, 152-157.	3.1	37
47	Risk Factors for Tunnel Infections in Continuous Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1991, 18, 344-348.	1.9	35
48	Biophysiologic Outcomes of the Enhancing Adherence in Type 2 Diabetes (ENHANCE) Trial. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2012, 112, 1147-1157.	0.8	35
49	Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 456-9.	2.3	35
50	Large body mass index does not predict short-term survival in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 191-6.	2.3	34
51	Peritoneal urea and creatinine clearances in continuous peritoneal dialysis patients with different types of peritoneal solute transport. <i>Kidney International</i> , 1998, 53, 1405-1411.	5.2	33
52	Tolerance of large exchange volumes by peritoneal dialysis patients. <i>American Journal of Kidney Diseases</i> , 1999, 33, 1136-1141.	1.9	30
53	A Preliminary Study of PDA-Based Dietary Self-Monitoring in Hemodialysis Patients. , 2005, 15, 304-311.		30
54	Vestibular Toxicity Due to Gentamicin in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1991, 11, 152-155.	2.3	29

#	ARTICLE	IF	CITATIONS
55	The Effect of the Y-Set on Catheter Infection Rates in Continuous Ambulatory Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 1990, 16, 46-50.	1.9	28
56	Calcium Mass Transfer With Dialysate Containing 1.25 and 1.75 mmol/L Calcium in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 1992, 20, 367-371.	1.9	28
57	Comparison of the Charlson Comorbidity Index and the Davies score as a predictor of outcomes in PD patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 568-73.	2.3	28
58	The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. <i>Clinical Cardiology</i> , 2006, 29, 494-497.	1.8	26
59	Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review. <i>Peritoneal Dialysis International</i> , 2020, 40, 132-140.	2.3	26
60	Inter-rater reliability and annual rescoring of the Charlson comorbidity index. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2004, 20, 125-7.	0.1	26
61	Peritoneal Infections. <i>Advances in Chronic Kidney Disease</i> , 2000, 7, 280-288.	2.1	24
62	The Use of Dialysate Containing 2.5 Meq/L Calcium in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1992, 12, 75-77.	2.3	23
63	Methicillin-Resistant Staphylococcal Infections in an Outpatient Peritoneal Dialysis Program. <i>American Journal of Kidney Diseases</i> , 1990, 16, 142-146.	1.9	22
64	Iatrogenic Peritonitis: The Need for Prophylaxis. <i>Peritoneal Dialysis International</i> , 2000, 20, 343-345.	2.3	22
65	An Analysis of Methods to Prevent Peritoneal Dialysis Catheter Infections. <i>Peritoneal Dialysis International</i> , 2008, 28, 437-443.	2.3	22
66	Peritonitis – Does Peritoneal Dialysis Modality Make a Difference?. <i>Blood Purification</i> , 2010, 29, 145-149.	1.8	22
67	Nutritional Intake in Adult Hemodialysis Patients. <i>Topics in Clinical Nutrition</i> , 2011, 26, 45-56.	0.4	22
68	The effect of depressive symptoms on survival in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2004, 24, 256-63.	2.3	22
69	Spontaneous hypercalcemia in patients undergoing dialysis. Etiologic and therapeutic considerations. <i>American Journal of Medicine</i> , 1986, 80, 607-615.	1.5	21
70	Alprazolam in End-Stage Renal Disease: I. Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 571-579.	2.0	21
71	Personal Digital Assistant-Based Self-Monitoring Adherence Rates in 2 Dialysis Dietary Intervention Pilot Studies: BalanceWise-HD and BalanceWise-PD. , 2011, 21, 492-498.		21
72	The economic value of screening haemodialysis patients for methicillin-resistant <i>Staphylococcus aureus</i> in the USA. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1717-1726.	6.0	21

#	ARTICLE	IF	CITATIONS
73	The Relation Between Body Size and Normalized Small Solute Clearances in Continuous Ambulatory Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1575-1581.	6.1	21
74	Clinical outcomes in peritoneal dialysis: impact of continuous quality provement initiatives. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2009, 25, 76-9.	0.1	21
75	<i>Clostridium difficile</i> Infections in Outpatient Dialysis Cohort. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 89-91.	1.8	20
76	Proposed health care financing administration guidelines for reimbursement of enteral and parenteral nutrition. <i>American Journal of Kidney Diseases</i> , 1995, 26, 995-997.	1.9	19
77	Ademex: How Should it Change our Practice?. <i>Peritoneal Dialysis International</i> , 2002, 22, 552-554.	2.3	19
78	Catheter Infections in Insulin-Dependent Diabetics on Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1991, 11, 347-350.	2.3	18
79	The United States' Perspectives on Home Dialysis. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 189-197.	1.4	18
80	Dietary Sodium Intake in Type 2 Diabetes. <i>Clinical Diabetes</i> , 2014, 32, 106-112.	2.2	18
81	Alprazolam in end-stage renal disease. II. Pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 533-540.	4.7	17
82	The Risks of Laparoscopic Cholecystectomy in Capd Compared with Hemodialysis Patients: A Study of Ten Patients. <i>Peritoneal Dialysis International</i> , 1994, 14, 395-396.	2.3	17
83	Organism-specific bacteremia by hemodialysis access. <i>Clinical Nephrology</i> , 2016, 86, 141-146.	0.7	17
84	Association of Kt/V and Creatinine Clearance With Outcomes in Anuric Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2008, 52, 1122-1130.	1.9	16
85	Management of catheter-related infections. <i>American Journal of Kidney Diseases</i> , 1996, 27, 754-758.	1.9	15
86	Complications of Peritoneal Dialysis: Diagnosis and Management. <i>Seminars in Dialysis</i> , 1990, 3, 245-248.	1.3	15
87	Insights on Peritoneal Dialysis-Related Infections. <i>Contributions To Nephrology</i> , 2009, 163, 161-168.	1.1	15
88	Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. <i>Peritoneal Dialysis International</i> , 2020, 40, 384-393.	2.3	15
89	Elevated Bone Aluminum and Suppressed Parathyroid Hormone Levels in Hypercalcemic Dialysis Patients. <i>American Journal of Nephrology</i> , 1989, 9, 190-197.	3.1	14
90	Increased Risk of Staphylococcus epidermidis Peritonitis in Patients on Dialysate Containing 1.25 mmol/L Calcium. <i>American Journal of Kidney Diseases</i> , 1992, 19, 371-374.	1.9	14

#	ARTICLE	IF	CITATIONS
91	Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Was it effective?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 349-352.	0.7	14
92	Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program. <i>Peritoneal Dialysis International</i> , 2016, 36, 387-389.	2.3	14
93	Patient Survival With Renal Replacement Therapy in Heart Transplantation Patients. <i>ASAIO Journal</i> , 1998, 44, M546-M548.	1.6	12
94	Peritoneal Dialysis Infections Recommendations. , 2006, 150, 181-186.		12
95	A PDA-based dietary self-monitoring intervention to reduce sodium intake in an in-center hemodialysis patient. <i>Patient Preference and Adherence</i> , 2008, 2, 177-84.	1.8	12
96	Improvement in Pittsburgh Symptom Score index after initiation of peritoneal dialysis. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2008, 24, 46-50.	0.1	12
97	A Dialysis Case Presentation and Discussionâ€”Edited by Roger A. Rodby: Peritoneal Dialysis Catheter Replacement: â€œSave the Patient and Not the Catheterâ€” <i>Seminars in Dialysis</i> , 2003, 16, 72-75.	1.3	11
98	Resolution of hypercalcemia and aluminum bone disease after renal transplantation. <i>American Journal of Medicine</i> , 1988, 85, 728-730.	1.5	10
99	Automated Peritoneal Dialysis Symposium: Intraâ€”abdominal Pressure, Peritoneal Dialysis Exchange Volume, and Tolerance in APD. <i>Seminars in Dialysis</i> , 2002, 15, 403-406.	1.3	10
100	New insights on preventing and managing peritonitis. <i>Pediatric Nephrology</i> , 2004, 19, 125-127.	1.7	10
101	Bleeding complications associated with peritoneal dialysis catheter insertion. <i>Peritoneal Dialysis International</i> , 2004, 24, 478-80.	2.3	10
102	An analysis of methods to prevent peritoneal dialysis catheter infections. <i>Peritoneal Dialysis International</i> , 2008, 28, 437-43.	2.3	10
103	National kidney foundation position paper on proposed health care financing administration guidelines for reimbursement of enteral and parenteral nutrition. , 1996, 6, 45-47.		9
104	Guest Editor: Beth Piraino: Why Is the Evidence Favoring Hemodialysis over Peritoneal Dialysis Misleading?. <i>Seminars in Dialysis</i> , 2007, 20, 200-202.	1.3	9
105	The importance of peritoneal catheter exit-site care. <i>Nature Reviews Nephrology</i> , 2010, 6, 259-260.	9.6	9
106	Review of Antibiotic Dosing with Peritonitis in APD. <i>Peritoneal Dialysis International</i> , 2019, 39, 299-305.	2.3	9
107	Hypercalcemia in Patients with Advanced Chronic Renal Failure Not Yet Requiring Dialysis. <i>American Journal of Nephrology</i> , 1989, 9, 205-210.	3.1	8
108	Innovations in Treatment Delivery, Risk of Peritonitis, and Patient Retention on Peritoneal Dialysis. <i>Seminars in Dialysis</i> , 2017, 30, 158-163.	1.3	8

#	ARTICLE	IF	CITATIONS
109	Peritoneal Catheter Exit-Site and Tunne Infections. <i>Advances in Chronic Kidney Disease</i> , 1996, 3, 222-227.	2.1	7
110	Initiating a Peritoneal Dialysis Program: Personnel, Administrative Requirements, Patient Recruitment and Training. <i>Seminars in Dialysis</i> , 1990, 3, 122-126.	1.3	7
111	Today's Approaches to Prevent Peritonitis. <i>Contributions To Nephrology</i> , 2012, 178, 246-250.	1.1	7
112	Comparison of Survival of Patients with Heart and Lung Transplants on Peritoneal Dialysis and Hemodialysis. <i>Peritoneal Dialysis International</i> , 2015, 35, 98-101.	2.3	7
113	Nightly intermittent peritoneal dialysis to initiate peritoneal dialysis. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2003, 19, 111-4.	0.1	7
114	Operating a Peritoneal Dialysis Program: Patient and Program Monitoring. <i>Seminars in Dialysis</i> , 1990, 3, 182-186.	1.3	6
115	Does Experience with Pd Matter?. <i>Peritoneal Dialysis International</i> , 2009, 29, 256-261.	2.3	6
116	Approaches to Preventing Peritonitis Based on Organism-Specific Rates. <i>Peritoneal Dialysis International</i> , 2011, 31, 636-638.	2.3	6
117	ADEMEX: how should it change our practice? Adequacy of Peritoneal Dialysis in Mexico. <i>Peritoneal Dialysis International</i> , 2002, 22, 552-4.	2.3	6
118	Gender Differences in Normalized Clearances in Capd: Role of Body Size and Normalizing Parameters. <i>Peritoneal Dialysis International</i> , 1999, 19, 165-169.	2.3	5
119	Peritoneal Dialysis Clearance can Replace Residual Renal Function. <i>Peritoneal Dialysis International</i> , 2001, 21, 263-268.	2.3	5
120	Cardiovascular Complications in Peritoneal Dialysis Patients. <i>Contributions To Nephrology</i> , 2009, 163, 102-109.	1.1	5
121	Sources of Variation in Estimates of Lean Body Mass by Creatinine Kinetics and by Methods Based on Body Water or Body Mass Index in Patients on Continuous Peritoneal Dialysis. , 2010, 20, 91-100.		5
122	A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2012, 60, 689-691.	1.9	5
123	Optimizing Peritoneal Dialysis's Associated Peritonitis Prevention in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 154-161.	4.5	5
124	Placement of peritoneal dialysis catheters on an outpatient basis. <i>Peritoneal Dialysis International</i> , 2002, 22, 616-8.	2.3	5
125	The Problem of Compliance with PD's Exchanges. <i>Seminars in Dialysis</i> , 2001, 13, 160-162.	1.3	4
126	Nurses and Physicians Working Together. <i>Peritoneal Dialysis International</i> , 2006, 26, 641-642.	2.3	4



#	ARTICLE	IF	CITATIONS
127	Does the risk of death differ between peritoneal dialysis and hemodialysis patients?. Nature Clinical Practice Nephrology, 2006, 2, 128-129.	2.0	4
128	Outcomes of PD Patients at 6 Months. Peritoneal Dialysis International, 2017, 37, 116-118.	2.3	4
129	Methods to determine drain volume for peritoneal dialysis clearances. Peritoneal Dialysis International, 2004, 24, 182-5.	2.3	4
130	Examination of survival after transfer from peritoneal dialysis to hemodialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2012, 28, 64-7.	0.1	4
131	Nasal Mupirocin: Its Role in Dialysis Patients. Seminars in Dialysis, 1997, 10, 145-147.	1.3	3
132	<i>Staphylococcus aureus</i> Prophylaxis in Dialysis Patients. Blood Purification, 2000, 18, 350-354.	1.8	3
133	Opinion: How Much Peritoneal Dialysis is Needed for Optimal Outcomes?. Seminars in Dialysis, 2003, 16, 367-369.	1.3	3
134	Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should be Changed?. Seminars in Dialysis, 2007, 20, 24-26.	1.3	3
135	How should peritoneal-dialysis-associated peritonitis be treated?. Nature Clinical Practice Nephrology, 2008, 4, 356-357.	2.0	3
136	Can We Reduce Rates of Staphylococcus Aureus and Other Peritonitis in Peritoneal Dialysis Patients?. Peritoneal Dialysis International, 2010, 30, 277-279.	2.3	3
137	Preventing peritonitis in PD patients. Dialysis and Transplantation, 2011, 40, 367-371.	0.2	3
138	Catheter-Related Peritonitis. Peritoneal Dialysis International, 2013, 33, 592-595.	2.3	3
139	Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. Clinical and Translational Science, 2022, 15, 649-657.	3.1	3
140	Hypercalcemia in a Dialysis Patient. American Journal of Nephrology, 1986, 6, 388-395.	3.1	2
141	Is Small Molecule Clearance Dependent on Timing of Serum Sample and Mixing of Effluent in Ccpd Patients?. Peritoneal Dialysis International, 1999, 19, 391-393.	2.3	2
142	Why is Peritoneal Dialysis Underutilized in the United States?. Dialysis and Transplantation, 2008, 37, 90-90.	0.2	2
143	In Reply to "A Large Dialysis Provider Committed to Home Modalities"™. American Journal of Kidney Diseases, 2012, 59, 739-740.	1.9	2
144	Loss of Kidney Function With Aging Is a Patient Safety Hazard. American Journal of Kidney Diseases, 2013, 62, 217-219.	1.9	2

#	ARTICLE	IF	CITATIONS
145	Effective Treatment of PD Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1919-1921.	4.5	2
146	The choice study. Peritoneal Dialysis International, 2006, 26, 423-5.	2.3	2
147	Nurses and physicians working together. Peritoneal Dialysis International, 2006, 26, 641-2.	2.3	2
148	An Intraperitoneal Insulin Regimen for Diabetics on Continuous Cyclic Peritoneal Dialysis. ASAIO Transactions, 1990, 36, 119.	0.2	1
149	An Introduction to the 2005 Peritoneal Dialysis-Related Infections Recommendations. Peritoneal Dialysis International, 2005, 25, 105-106.	2.3	1
150	Criminal Background Checks Upon Acceptance to Medical School: The Right Policy at the Right Time. Academic Medicine, 2011, 86, 807.	1.6	1
151	Putting Peritoneal Dialysis Catheter Infections Into Perspective. American Journal of Kidney Diseases, 2019, 74, 705-707.	1.9	1
152	Does experience with PD matter?. Peritoneal Dialysis International, 2009, 29, 256-61.	2.3	1
153	Transferring From Peritoneal Dialysis to Hemodialysis: Proceed With Caution. Kidney International Reports, 2022, 7, 942-944.	0.8	1
154	Managing Staphylococcus aureus Catheter Infection in Continuous Ambulatory Peritoneal Dialysis Patients. Advances in Chronic Kidney Disease, 1994, 1, 167-175.	2.1	0
155	Research Directions in Peritoneal Dialysis Infections. Blood Purification, 1995, 13, 171-179.	1.8	0
156	Outcomes of renal replacement therapy in orthotopic heart transplant patients. Current Opinion in Critical Care, 1998, 4, 364-367.	3.2	0
157	Dialysis Clinic: Cefazolin Use in Methicillin-Resistant Staphylococcal Peritonitis. Seminars in Dialysis, 2003, 16, 411-412.	1.3	0
158	The Prevention of <i>Staphylococcus aureus</i> Peritoneal Dialysis-Related Infections. Seminars in Dialysis, 1995, 8, 355-358.	1.3	0
159	Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should be Changed?. Seminars in Dialysis, 2007, 20, 28-30.	1.3	0
160	Why Is the Evidence Favoring Hemodialysis over Peritoneal Dialysis Misleading?. Seminars in Dialysis, 2007, 20, 202-205.	1.3	0
161	On Being a Nephrologist. Dialysis and Transplantation, 2009, 38, 112-112.	0.2	0
162	When should the peritoneal dialysis catheter be removed for dialysis-related infections?. Seminars in Dialysis, 2011, 24, 443-444.	1.3	0

#	ARTICLE	IF	CITATIONS
163	Learning from the Children. <i>Peritoneal Dialysis International</i> , 2012, 32, 395-398.	2.3	0
164	Preparing for Peritoneal Dialysis. , 2020, , 1175-1185.		0
165	The mystery of the nonfunctioning catheter: An unusual complication of peritoneal dialysis outflow failure. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2017, 28, 405.	0.3	0